文献速递浆细胞疾病

Mayo MASS与R2-ISS分期系统在初诊多发性骨髓瘤患者中预后价值的验证:单中心研究

[Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

纳入371例初诊多发性骨髓瘤患者,采用胞质轻链免疫荧光结合荧光原位杂交检测细胞遗传学异常,验证Mayo MASS与R2-ISS分期的预后价值。R-ISS、Mayo MASS和R2-ISS各期患者的中位无进展生存与总生存均随分期升高而缩短,差异有统计学意义。作者认为Mayo MASS和R2-ISS在R-ISS基础上纳入1q21+使分期更完善,但两系统Ⅲ期患者比例偏高,考虑与中国人群1q21+发生率和ISS Ⅲ期比例较高相关。

要点

  • R2-ISS Ⅰ、Ⅱ、Ⅲ、Ⅳ期中位PFS分别为47、31、25、15个月(P=0.001)。
  • Mayo MASS Ⅰ、Ⅱ、Ⅲ期中位PFS分别为43、27、19个月(P<0.001)。
  • 作者认为Mayo MASS和R2-ISS纳入1q21+后分期更完善,但Ⅲ期比例偏高。

核心结论

  • 基于R-ISS分期系统,Mayo MASS和R2-ISS预后分期系统纳入1q21+,可进行更好的分层。
  • Mayo MASS和R2-ISS分期系统下Ⅲ期患者比例偏高,作者认为与中国MM患者1q21+发生率和ISS Ⅲ期比例较高相关。

研究设计与样本

  • 单中心研究,纳入南京医科大学第一附属医院371例初诊多发性骨髓瘤患者。
  • 采用胞质轻链免疫荧光结合荧光原位杂交(cIg-FISH)检测细胞遗传学异常,结合临床资料分析疾病分期并评估预后。

主要发现

  • R-ISS Ⅰ、Ⅱ、Ⅲ期分别有37例(10.0%)、264例(71.2%)、70例(18.8%),中位PFS分别为37、31、14个月(P=0.001),中位OS分别为未达到(NR)、66、31个月(P<0.001)。
  • Mayo MASS Ⅰ、Ⅱ、Ⅲ期分别有71例(19.1%)、140例(37.7%)、160例(43.2%),中位PFS分别为43、27、19个月(P<0.001),中位OS分别为NR、NR、35个月(P<0.001)。
  • R2-ISS Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别有23例(6.2%)、69例(18.6%)、222例(59.8%)、57例(15.4%),中位PFS分别为47、31、25、15个月(P=0.001),中位OS分别为NR、NR、49、55个月(P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the prognostic value of Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma (MM) . Methods: A total of 371 patients newly diagnosed with MM in Jiangsu Province Hospital were included in the study. Cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization (cIg-FISH) was performed to detect cytogenetic abnormality. Clinical characteristics were combined to analyze the disease stage and evaluate the prognosis. Results: There were 37 (10.0%), 264 (71.0%), and 70 (18.8%) patients in R-ISS stage Ⅰ, Ⅱ, and Ⅲ, respectively. The median progression-free survival (PFS) times were 37, 25, and 14 months (P<0.001). The median overall survival (OS) times were not reached (NR), 66, and 30 months (P<0.001). There were 71 (19.1%), 140 (37.7%), and 160 (43.2%) patients in Mayo MASS stages Ⅰ, Ⅱ, and Ⅲ, and the median PFS times periods were 43, 27, and 19 months (P<0.001), and the median OS times were NR, NR, 35 months, respectively (P<0.001). There were, 23 (6.2%), 69 (18.6%), 222 (59.8%), and 57 (15.4%) patients in R2-ISS stages Ⅰ, Ⅱ, Ⅲ, and Ⅳ, respectively. The median PFS times were 47, 31, 25, and 15 months (P=0.001), and the median OS times were NR, NR, 49, and 55 months, respectively (P<0.001) . Conclusion: Based on the R-ISS staging system, Mayo MASS, and R2-ISS prognostic staging system incorporated 1q21+, which allows a better stratification. However, the proportion of stage Ⅲ patients in Mayo MASS and R2-ISS staging systems is relatively high, which is considered related to the high incidence of 1q21+ and ISS Ⅲ in the Chinese population. 目的: 验证Mayo MASS、R2-ISS分期系统在初诊多发性骨髓瘤(MM)患者中的预后价值。 方法: 纳入南京医科大学第一附属医院收治的371例初诊MM患者,胞质轻链免疫荧光结合荧光原位杂交(cIg-FISH)检测患者的细胞遗传学特征,结合患者的临床资料分析其疾病分期并评估预后。 结果: R-ISS分期Ⅰ、Ⅱ、Ⅲ期患者分别有37例(10.0%)、264例(71.2%)和70例(18.8%),中位无进展生存(PFS)时间分别为37、31和14个月(P=0.001),中位总生存(OS)时间分别为未达到(NR)、66个月和31个月(P<0.001)。Mayo MASS分期Ⅰ、Ⅱ、Ⅲ期患者分别有71例(19.1%)、140例(37.7%)和160例(43.2%),中位PFS时间分别为43、27和19个月(P<0.001),中位OS时间分别为NR、NR和35个月(P<0.001)。R2-ISS分期Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者分别有23例(6.2%)、69例(18.6%)、222例(59.8%)和57例(15.4%),中位PFS时间分别为47、31、25和15个月(P=0.001),中位OS时间分别为NR、NR、49个月和55个月(P<0.001)。 结论: Mayo MASS和R2-ISS分期系统在R-ISS分期基础上纳入了1q21+,分期更完善,但两种分期系统下Ⅲ期患者比例偏高,考虑与中国MM患者1q21+发生率和ISS Ⅲ期比例较高相关。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xu Y, Shen XX, Jin YY, et al. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38049319. doi:10.3760/cma.j.issn.0253-2727.2023.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。